- Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancerMeijun, Du; Yijun, Tian; Winston, Tan; Liewei, Wang; Liguo, Wang; Deepak, Kilari; Chiang-Ching, Huang; Liang, Wang; Manish, KohliPROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23(4): 705-713.被引 2
- Phase II therapeutic equivalence study of Abiraterone Acetate Tablets (I) vs. ZYTIGA? in patients with metastatic castration-resistant prostate cancer.Ye, Dingwei; Bian, Xiaojie; Han, Weiqing; Bin Wu; Chen, Hui; Wu, Jitao; Yu, Dexin; Ge, Huixin; Li, Jian; Huang, Houbao; Fan, Tiwu; Cheng, Linzhong; Zhang, Xiaoping; Zhang, Xuepei; Yao, Xin; Wei, Junli; Xu, Zhenqiang; Mu, Peilei; Huang, Rong; Wang, HuanAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Neuroendocrine Differentiation in the Progression of Prostate Cancer: An Update on Recent DevelopmentsValérie, PerrotOpen Journal of Urology, 2012, 02(03): 173-182.被引 1
期刊论文
Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma
12阅读
